Last reviewed · How we verify
Bupivacaine Hydrochloride 0.75% Injection Solution
Bupivacaine Hydrochloride 0.75% Injection Solution, marketed by Oregon Health and Science University, is a well-established anesthetic in the healthcare sector. The key composition patent is set to expire in 2028, providing a significant period of market protection. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Bupivacaine Hydrochloride 0.75% Injection Solution |
|---|---|
| Also known as | Marcaine spinal |
| Sponsor | Oregon Health and Science University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Spinal Anesthesia For Enhanced Recovery After Liver Surgery (NA)
- Saddle Block With IT Morphine for Penile Inversion Vaginoplasty (NA)
- Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers (PHASE1)
- Radiofrequency Applications and Alcoholic Neurolysis of Genicular Nerve for the Treatment of Knee Osteoarthritic Pain (NA)
- Pericapsular Nerve Block Versus Intrathecal Morphine for Analgesia After Primary Hip Arthroplasty (NA)
- Comparison of Clorotekal and Bupivacaine for Short Obstetric Surgery (PHASE4)
- The Post Cesarean Section Analgesic Effect of Various Quadratus Lumborum Block Approaches
- Comparing Two Regional Anesthesia Interventions for Knee Arthroplasty. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: